Standard Operating Procedure for Line Extension Evaluation and Regulatory Filing
| Department | Regulatory Affairs |
| SOP No. | RA/2026/671 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 11/04/2026 |
| Effective Date | 11/04/2026 |
| Review Date | 11/04/2028 |
Purpose
This Standard Operating Procedure (SOP) outlines the systematic approach for the evaluation of line extensions and the subsequent regulatory filing processes. It supports the control objective of ensuring that all line extension activities comply with applicable regulatory requirements and internal company quality systems to maintain product integrity and regulatory compliance throughout the product lifecycle.
Scope
This SOP applies to all line extension evaluations and regulatory submission activities within the Regulatory Affairs department. It encompasses assessment of new strengths, indications, dosage forms, packaging changes, or any other product modifications requiring regulatory notification or approval. The SOP includes cross-functional coordination with Quality Assurance, Manufacturing, and other relevant departments. Activities excluded are line extensions not requiring regulatory filings and post-approval changes not classified under line extensions.
Responsibilities
- Regulatory Affairs Team: Execute evaluation and prepare regulatory submissions.
- Quality Assurance: Review and approve evaluation outcomes and support documentation control.
- Manufacturing/Technical Departments: Provide technical input and data for evaluation.
- Regulatory Manager: Supervise the process and ensure compliance with regulatory standards.
- Document Control: Manage version control and archiving of SOP and related records.
Accountability
The Regulatory Affairs Head holds overall accountability for the implementation, compliance monitoring, periodic review, escalation of issues, and effectiveness of this SOP in alignment with company policies and applicable regulatory frameworks.
Procedure
The procedure for line extension evaluation and regulatory filing shall be conducted as follows:
1. Preparation and Initiation: Upon identification of a potential line extension opportunity, the Regulatory Affairs team shall receive a formal request or proposal from product management or relevant stakeholders. Preliminary information and data required for evaluation must be collected, including technical dossiers, clinical or stability data, comparative analyses, and justification for the extension.
2. Eligibility and Impact Assessment: Conduct a thorough assessment to determine the regulatory status of the proposed line extension. Identify applicable regulatory pathways, requirements, and timelines based on jurisdiction. Evaluate impact on existing product licenses, labeling, manufacturing processes, and quality systems.
3. Cross-Functional Coordination: Engage subject matter experts from Quality Assurance, Manufacturing, Clinical, and Supply Chain for in-depth evaluation and data validation. Hold review meetings to discuss findings, potential risks, and mitigation strategies. Document all outcomes and decisions.
4. Preparation of Regulatory Submission: Compile a comprehensive submission dossier according to regulatory authority guidelines. This shall include the cover letter, summary of changes, updated product information, stability data, risk assessments, and any required forms or declarations. Ensure accuracy and completeness of documents.
5. Quality and Compliance Checks: Perform GMP and quality compliance verification before submission. Validate that all supporting documents meet internal standards and external regulatory expectations. Confirm that documentation is current and version controlled.
6. Submission and Follow-up: Submit regulatory filings through the designated regulatory submission systems or channels. Record submission details with dates and acknowledgment references. Monitor progress and respond promptly to queries or requests from the regulatory authority.
7. Approval and Implementation: Upon receipt of regulatory approval or authorization, communicate decisions to all relevant departments. Update internal documentation, labelling, and training materials accordingly. Implement any changes as per approved documentation ensuring traceability.
8. Documentation and Record Keeping: Maintain all records related to the line extension evaluation and regulatory filing in a secure, retrievable, and compliant manner. This includes evaluation reports, correspondence, submission dossiers, approvals, and internal approvals or review notes. Records retention shall comply with applicable regulatory and company policies.
9. Deviation Handling and Escalation: Any deviations or non-conformances encountered during the process shall be immediately reported and managed as per the company’s deviation and CAPA procedures. Escalate critical issues to the Regulatory Affairs Head for resolution.
10. Review and Continuous Improvement: This SOP and the overall process shall undergo periodic review to ensure alignment with changing regulations and company objectives. Feedback and lessons learned from each line extension shall be collected and used to enhance this procedure.
Abbreviations
- GMP – Good Manufacturing Practice
- CAPA – Corrective and Preventive Action
- QA – Quality Assurance
- RA – Regulatory Affairs
- SOP – Standard Operating Procedure
Documents
Documents required specifically for line extension evaluation and regulatory filing are:
- Line Extension Evaluation Report (Annexure-1)
- Regulatory Submission Checklist (Annexure-2)
- Regulatory Filing Cover Letter Template (Annexure-3)
References
- ICH Q10 Pharmaceutical Quality System Guidelines
- FDA Guidance for Industry on Post-Approval Changes
- EMA Guideline on Variations and Line Extensions
- Company Quality Management System Documentation
- Applicable National and International Regulatory Requirements
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Line Extension Evaluation Report
Purpose: To document the detailed assessment of a proposed line extension, including technical, regulatory, and quality considerations.
| Line Extension ID | LE-2026-042 |
| Product Name | Example Drug |
| Proposed Extension Type | New Strength – 50 mg |
| Initiation Date | 01/03/2026 |
| Evaluation Team Members | Regulatory Affairs, QA, Manufacturing |
| Summary of Assessment | Technical dossier complete; no major manufacturing changes; stability data supports shelf life; regulatory pathway identified as Type II variation. |
| Potential Risks Identified | Labeling update required, supply chain adjustment needed. |
| Recommendations | Proceed with regulatory submission as per identified pathway. |
| Date of Report Completion | 10/03/2026 |
| Reviewed By (Role) | Quality Assurance Reviewer |
| Approval Status | Approved |
Annexure-2: Regulatory Submission Checklist
Purpose: To verify completeness and compliance of all required documents before regulatory filing.
| Document | Status (Yes/No) | Comments |
|---|---|---|
| Cover Letter | Yes | Completed with accurate information |
| Updated Product Dossier | Yes | Includes new strength details |
| Stability Data | Yes | Validated per protocol |
| Risk Assessment | Yes | Comprehensive and approved |
| Labeling Updates | Yes | Draft reviewed |
| Regulatory Forms | Yes | Submitted as per authority requirements |
| Signatures and Approvals | Yes | All required approvals obtained |
Annexure-3: Regulatory Filing Cover Letter Template
Purpose: To serve as a formal communication letter accompanying the regulatory submission for a line extension.
| Date: | 11/04/2026 |
| To: | Regulatory Authority |
| Subject: | Submission of Line Extension Application for [Product Name] |
| Reference: | Application No. [To be assigned] |
|
Dear Sir/Madam, We hereby submit the application for a line extension of the product [Product Name], proposed as a new strength of 50 mg. The submission package includes all required documentation as per guidelines. Please find enclosed the detailed dossier, stability data, product labeling, and risk assessments supporting this extension. We request your kind review and approval at the earliest convenience. Should you require any additional information, please do not hesitate to contact our Regulatory Affairs department. Sincerely, Regulatory Affairs Team |
|
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 11/04/2026 | 1.0 | Initial issue | New SOP creation |